This critique evaluates a retrospective observational study on the impact of extracorporeal membrane oxygenation (ECMO) treatments on acquired von Willebrand syndrome (AVWS) in patients with out-of-hospital cardiac arrest (OHCA). The study is praised for its detailed observational methodology, robust statistical analyses, and comprehensive overview of patient outcomes. These strengths enhance the applicability of the results to real-world clinical practice. However, the study's retrospective design poses inherent risks of bias and confounding factors, which the authors acknowledge but do not extensively address. The absence of a control group of OHCA patients who did not receive ECMO is a significant limitation, as it weakens the ability to isolate the impact of ECMO on AVWS development. Additionally, a more in-depth exploration of the mechanisms by which ECMO contributes to AVWS is needed. Despite these limitations, the study contributes valuable insights into ECMO-related complications and underscores the necessity for vigilant management strategies to mitigate AVWS risks in this high-risk population. The critique concludes by calling for future prospective studies and the development of preventative protocols to improve patient outcomes in ECMO-treated OHCA patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11577710 | PMC |
http://dx.doi.org/10.1186/s12959-024-00673-w | DOI Listing |
J Heart Lung Transplant
December 2024
DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, 13353 Berlin, Germany; Deutsches Herzzentrum der Charité, Department of Cardiothoracic and Vascular Surgery, Berlin, Germany. Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Charitéplatz 1, 10117 Berlin, Germany.
Background: Temporary mechanical circulatory support (tMCS) devices have become a standard treatment option in cardiogenic shock but are associated with high complication rates. This study analyzes common complications associated with modern tMCS devices and their impact on mortality depending on the tMCS approach.
Methods: We conducted a retrospective single-center analysis of patients with all-cause cardiogenic shock treated with veno-arterial extracorporeal life support, microaxial flow pump, and a combination of both (ECMELLA).
J Orthop Sports Phys Ther
January 2025
Midportion tendinopathy is a common overuse lower extremity injury, with a prevalence of 4% to 7%. Achilles tendinopathy especially affects people who participate in activities that load the Achilles tendon, such as running. The Victorian Institute of Sport Assessment-Achilles (VISA-A) questionnaire has been the go-to patient-reported outcome measure of the perceived impact of Achilles tendinopathy.
View Article and Find Full Text PDFFront Pharmacol
December 2024
ADVITOS GmbH, Munich, Germany.
Background: Acute kidney injury (AKI) requiring continuous renal replacement therapy is common in critically ill patients. The ADVanced Organ Support (ADVOS) system is a novel hemodialysis machine that uses albumin enriched dialysate which allows the removal of protein-bound toxins and drugs. To date, data on antimicrobial removal under ADVOS has not yet been reported.
View Article and Find Full Text PDFInfect Drug Resist
December 2024
Department of Critical Care Medicine, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, People's Republic of China.
Purpose: With the development of extracorporeal membrane oxygenation (ECMO) technology, the duration of ECMO support has gradually increased, leading to an increased risk of ECMO-related bacterial resistance. Polymyxin B (PMB) is used to treat drug-resistant bacterial infections. However, the pharmacokinetic (PK) parameters of antibiotics may change during ECMO, resulting in over- or under-exposure.
View Article and Find Full Text PDFJ Cardiovasc Dev Dis
December 2024
3rd Department of Cardiology, "Sotiria" Chest Diseases Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Hypertrophic cardiomyopathy (HCM) is a complex and heterogeneous cardiac disorder, often complicated by cardiogenic shock, a life-threatening condition marked by severe cardiac output failure. Managing cardiogenic shock in HCM patients presents unique challenges due to the distinct pathophysiology of the disease, which includes dynamic left ventricular outflow tract obstruction, diastolic dysfunction, and myocardial ischemia. This review discusses current and emerging therapeutic strategies tailored to address the complexities of HCM-associated cardiogenic shock and other diseases with similar pathophysiology that provoke left ventricular outflow tract obstruction.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!